Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Janssen (J&J Innovative Medicine)

Status

Conditions: Relapsed or Refractory Multiple Myeloma

Treatments: Drug: Teclistamab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05463939

CR109154

64007957MMY4001 (Other Identifier)

Details and patient eligibility

About

The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patient diagnosed with Relapsed or Refractory Multiple Myeloma
• Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial